Drugs / Bcr-abl multipeptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00455221 | Feb 2008 → Dec 2010 | chronic myeloid leukemia | Tehran University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bcr-abl multipeptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00455221 ↗ |
| Modality | Vaccine | “peptide-gene vaccine against CML” NCT00455221 ↗ |
| Route | Subcutaneous | “One constant dose of ten bcr-abl peptides (100μg each) will be administered subcutaneously in all patients triweekly for 8 doses” NCT00455221 ↗ |